← Leaderboards
Chetan Bettegowda
Johns Hopkins University
$9,213,403
Attributed
$19,516,910
Total exposure
10
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4M · FY2016–25$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,986,303 · 9
FDA$2,530,607 · 1
By mechanism
U01$9,643,387 · 2
R01$4,527,116 · 2
R37$2,584,589 · 1
R21$1,294,519 · 3
R42$1,148,055 · 1
UE5$319,244 · 1
Top collaborators
- Nickolas Papadopoulos8 shared
- Amitabh Chak4 shared
- Stuart A Grossman4 shared
- Sanford D Markowitz4 shared
- Nicholas J Shaheen4 shared
- Peter W. Stacpoole4 shared
- Sachin Wani4 shared
- Nishant Agrawal3 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Argye E. Hillis$28,779,519
- David Sidransky$59,922,938
- Jinyuan Zhou$11,995,343
- Susumu Mori$21,124,041
- Laurie E Cutting$31,769,016
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsDiagnosisDetectionTumor DnaMutationDiagnosticTumorSamplingCerebrospinal FluidBurden Of IllnessMinimally InvasiveTissuesMalignant Neoplasm Of BrainBloodBiopsySpecific BiomarkersSomatic MutationAneuploidyRecurrenceLiquid BiopsyBiological MarkersCohortPlasmaCancer Cell
Grant awards (34)
Validation of Biomarkers for predicting Barrett's esophagus that will or will not: i) progress towards cancer, or ii) recur after ablation$1,048,823
U01 · FY2025 · CA
Multi-omic CSF Assay for the Diagnosis of Brain Cancers$844,210
R42 · FY2025 · NS
Multi-analyte Approach for Earlier Detection of Cancers in Non Plasma Biofluids$708,799
U01 · FY2025 · CA
Integrating circulating tumor DNA assay and protein-based MRI to accurately monitor glioma therapy$669,307
R01 · FY2025 · CA
Research Education Program for Residents and Fellows in Neurology$319,244
UE5 · FY2025 · NS
Validation of Biomarkers for predicting Barrett's esophagus that will or will not: i) progress towards cancer, or ii) recur after ablation$996,868
U01 · FY2024 · CA
Phase IIA Trial of Dichloroacetate for Glioblastoma Multiforme, IND137007, 09172019$669,027
R01 · FY2024 · FD
Integrating circulating tumor DNA assay and protein-based MRI to accurately monitor glioma therapy$635,842
R01 · FY2024 · CA
Multi-analyte Approach for Earlier Detection of Cancers in Non Plasma Biofluids$415,618
U01 · FY2024 · CA
Interrogating malignant gliomas using released tumor DNA in cerebrospinal fluid$355,850
R37 · FY2024 · CA · contact PI
Multi-omic CSF Assay for the Diagnosis of Brain Cancers$303,845
R42 · FY2024 · NS
Validation of Biomarkers for predicting Barrett's esophagus that will or will not: i) progress towards cancer, or ii) recur after ablation$1,028,348
U01 · FY2023 · CA
Multi-analyte Approach for Earlier Detection of Cancers in Non Plasma Biofluids$987,109
U01 · FY2023 · CA
Integrating circulating tumor DNA assay and protein-based MRI to accurately monitor glioma therapy$691,360
R01 · FY2023 · CA
Phase IIA Trial of Dichloroacetate for Glioblastoma Multiforme, IND137007, 09172019$660,372
R01 · FY2023 · FD
Interrogating malignant gliomas using released tumor DNA in cerebrospinal fluid$367,087
R37 · FY2023 · CA · contact PI
Cell-free DNA-Based Analysis for Diagnosis, Monitoring and Optimization of Therapy for Patients with Primary Central Nervous System Lymphomas$245,625
R21 · FY2023 · TR · contact PI
Validation of Biomarkers for predicting Barrett's esophagus that will or will not: i) progress towards cancer, or ii) recur after ablation$781,052
U01 · FY2022 · CA
Earlier Detection of Cancers using Non-Plasma Based Liquid Biopsies$721,220
U01 · FY2022 · CA
Phase IIA Trial of Dichloroacetate for Glioblastoma Multiforme, IND137007, 09172019$659,650
R01 · FY2022 · FD
Interrogating malignant gliomas using released tumor DNA in cerebrospinal fluid$374,578
R37 · FY2022 · CA · contact PI
Cell-free DNA-Based Analysis for Diagnosis, Monitoring and Optimization of Therapy for Patients with Primary Central Nervous System Lymphomas$204,687
R21 · FY2022 · TR · contact PI
Earlier Detection of Cancers using Non-Plasma Based Liquid Biopsies$736,145
U01 · FY2021 · CA
Phase IIA Trial of Dichloroacetate for Glioblastoma Multiforme, IND137007, 09172019$541,558
R01 · FY2021 · FD
Interrogating malignant gliomas using released tumor DNA in cerebrospinal fluid$374,578
R37 · FY2021 · CA · contact PI
Earlier Detection of Cancers using Non-Plasma Based Liquid Biopsies$736,346
U01 · FY2020 · CA
Interrogating malignant gliomas using released tumor DNA in cerebrospinal fluid$374,578
R37 · FY2020 · CA · contact PI
Earlier Detection of Cancers using Non-Plasma Based Liquid Biopsies$714,445
U01 · FY2019 · CA
MRgFUS-enabled non-invasive interrogation of malignant glioma via circulating tumor DNA$453,531
R21 · FY2019 · NS · contact PI
Interrogating malignant gliomas using released tumor DNA in cerebrospinal fluid$363,340
R37 · FY2019 · CA · contact PI
Earlier Detection of Cancers using Non-Plasma Based Liquid Biopsies$768,614
U01 · FY2018 · CA
Interrogating malignant gliomas using released tumor DNA in cerebrospinal fluid$374,578
R37 · FY2018 · CA · contact PI
(PQ 6) Exploiting Frequent Alterations in the PRC2 Complex to Distinguish Benign Neurofibromas from Malignant Peripheral Nerve Sheath Tumors$177,852
R21 · FY2017 · CA · contact PI
(PQ 6) Exploiting Frequent Alterations in the PRC2 Complex to Distinguish Benign Neurofibromas from Malignant Peripheral Nerve Sheath Tumors$212,824
R21 · FY2016 · CA · contact PI